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Summary. Early knee osteoarthritis and chondral lesions are a common cause of disability in younger pa-
tients. Surgical options, such as microfractures, ACI and OAT, provide good, but not fully satisfying, out-
comes. Recent advance in biological knowledge introduced two different methodological approaches of de-
livering growth factors and stem cells into the articular environment. Platelet-Rich Plasma and Mesenchimal 
Stem Cells are supposed to change the way to approach early knee osteoarthritis and chondral lesions, though 
their indications and limits are yet to be determined. (www.actabiomedica.it)
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Introduction
The knee is the most common site of osteoarthri-
tis (OA). The PRO.V.A. study estimated a prevalence 
of 20,4% of knee osteoarthritis in people aged 65 years 
or older in Italy (1). The 2010 EULAR recommenda-
tions for diagnosis of knee OA (KOA) (2) and recent 
research (3) suggest to consider it as a whole joint dis-
ease, characterized by cartilage loss, subchondral bone 
remodeling, osteophyte formation and involvement of 
soft tissues such as synovial inflammation and meniscal 
degeneration (4). KOA is the result of imbalance be-
tween catabolic and repair process; the main risk fac-
tor is aging, but the decay is accelerated by mechanical 
factors, such as lower limb malalignment and articular 
trauma, and systemic diseases, such as metabolic (dia-
betes, obesity…) or autoimmune (rheumatoid arthri-
tis, …) pathologies. These individuals are at higher risk 
of developing KOA at an earlier age, with more severe 
symptoms, though they could manifest after a long 
time from the “primum movens”, as for radiographic 
and macroscopic changes. Since there are no disease 
modifying drugs and patients eventually undergo total 
knee replacement, there is a rising interest in detecting 
and treating early stages of KOA (3). 
Cartilage defects can cause significant disability 
and predispose to KOA. Severity correlates with thick-
ness of articular damage: superficial lesions do not heal 
but often are poorly or not symptomatic at all, while 
full thickness defects usually heal forming fibrous car-
tilage but yielding more severe consequences (47). Pa-
tients with small lesions are more likely to be asympto-
matic after restoration of cartilage, even though it’s not 
hyaline tissue (23). Larger defects are usually a pain-
ful and limiting condition, leading to an impairment 
in joint homeostasis towards decaying process. In the 
long time, such lesions are going to yield the onset of 
KOA (22).
Several surgical treatments have been proposed 
to regenerate articular cartilage: microfractures, au-
tologous chondrocyte implantation and osteochondral 
transplants.
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Microfractures (MF)
Microfracture is the most widely used marrow-
stimulation procedure. MF is usually performed with 
tapered awls with conical drill holes 0.5 to 1 mm in 
diameter, 4 mm deep, and approximately 3 to 4 mm 
apart. Holes are made in the lesion starting from the 
periphery to the lesion’s center (5) to provide blood 
supply to the defect, with formation of a clot. Healing 
process evolves in fibrous cartilage formation.
It is often considered a gold standard treatment 
option for smaller and contained cartilage lesions giv-
en the ease and low cost of the procedure as well as 
the good short-term outcomes demonstrated with this 
procedure (6). Several studies show good outcomes 
improvement both in midterm and long term follow 
up (7-10). 
Autologous chondrocyte implantation (ACI)
Autologous chondrocyte implantation is indi-
cated for larger lesions according to many surgeons. It 
was initially performed as a 2-steps process in which 
the first procedure involves knee arthroscopic surgery 
with collection of a cartilage biopsy specimen (11). The 
location of the biopsy sample is taken from the margin 
of the trochlea. After the culture of autogenous chon-
drocytes, the second stage of the procedure involves 
knee arthrotomy for implantation of the expanded 
chondrocytes. This involves removal of a flap of perios-
teum from the patient’s tibia and using it to cover the 
newly implanted chondrocytes (12). A new generation 
matrix-associated ACI (M-ACI) is now available. This 
procedure is similar, although rather than using a peri-
osteal patch, chondrocytes are seeded on a hyaluronic 
acid–based scaffold to obtain the bioengineered tis-
sue. This graft is positioned within the defect location, 
where it remains tightly adhered without necessitating 
fibrin glue or sutures to fix the implant (13, 14).
Osteochondral transplants
Reconstruction techniques, including osteochon-
dral autograft transplantation as well as osteochondral 
allograft transplantation (OAT), are surgical solutions 
that address both the cartilage and the osseous com-
ponents of the injury. The autograft option is attractive 
in that it is a single-stage procedure that involves the 
harvest of osteoarticular plugs from a nonarticulating 
portion of the knee, followed by the placement of these 
plugs into the defect site; no foreign tissue is required 
(15). Given the need to use the healthy osteoarticu-
lar plugs from the patient, this technique may be best 
suited for smaller (\2 cm2) lesions, and certainly, there 
is some concern over donor-site morbidity.
With advances in surgical instrumentation and 
expanding indications, OAT is being performed with 
increasing frequency. The benefits of OAT are many, 
including the ability to treat larger defects, lack of do-
nor-site morbidity and reduced surgical time, and abil-
ity to customize the graft to the recipient’s defect site. 
Further, many authors have reported good to excellent 
clinical outcomes after primary OAT, after OAT as 
a salvage procedure for failed prior cartilage restora-
tion, and after OAT combined with meniscus allograft 
transplantation (MAT) (16-18).
However, some concerns over OAT remain, in-
cluding cost concerns, unavailability of allograft tissue, 
and disease transmission. The overall complication rate 
after OAT is low (19); however, one of the more poorly 
understood complications after OAT is the need for 
reoperations.
Low friction, resistance to wear and absorption 
of stresses are mechanical properties required for a 
functional cartilage tissue. Benefits derived from these 
procedures are different, depending from the repair 
tissue obtained and strictly related to the technique 
used. MF is considered to produce a clot from sub-
chondral bleeding, containing growth factors, but 
resulting in a fibrous cartilage, with poor mechani-
cal properties. On the other hand ACI and OAT 
should produce a more hyaline-like tissue, at a cost 
of a higher invasivity. However, differences in carti-
lage quality seems not to affect clinical results (20). 
Several randomized studies compared the treatments 
mentioned above, mainly MF and ACI (20-24). Inde-
pendently from the treatment, were it MF or ACI or 
OAT, patients outcomes were similar, with no statisti-
cally significant difference in clinical scores and failure 
rates. Furthermore, Knutsen et al (20) found out no 
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difference in histological quality of repair tissue in pa-
tients with or without a failure of treatment. For these 
reasons, lack of blood supply and low metabolic po-
tential, that should protect cartilage in a healthy joint 
environment, are believed to compromise the success 
of surgical treatments, whatever it is, and joint re-
placement is often ultimately required. Moreover, bi-
ologic response to treatments correlates with “age” of 
the lesions: patients who are symptomatic for a longer 
time are less likely to benefit from any intervention 
(21). For these reasons, thanks to a deeper knowledge 
about biologic processes, methods to enhance cellu-
lar response are developing. The two main sources of 
biological support, used to provide hyaline cartilage 
restoration, were identified in platelet-rich plasma and 
mesenchymal stem cells. 
PRP
Platelet-rich plasma (PRP) is derived from a 
sample of autologous blood prepared until its con-
centration of platelets is above base-line values. It is 
theorized that higher levels of platelets can allow for 
release of growth factors, which may promote angio-
genesis and soft tissue healing. Results have indicated 
a beneficial effect of PRP on chondrocytes and mesen-
chymal stem cells. PRP also promotes differentiation 
of subchondral bone progenitor cells. Kruger et al. not 
only demonstrated that PRP significantly stimulated 
the migration of human progenitor cells in chemot-
axis assays, but also showed that histological staining 
revealed increased cartilage matrix formation in cells 
treated with PRP compared with untreated progeni-
tor controls (25). Furthermore, Anitua et al. reported 
that synoviocytes from patients with osteoarthritis 
(OA) cultured in PRGF demonstrated an increase in 
hyaluronan (HA) production. The authors proposed 
that intra-articular administration of PRP might be 
beneficial in restoring hyaluronic acid concentration 
and serve as an endogenous source of chondropro-
tection and joint lubrication. The inconsistent results 
between studies, however, demonstrate that, although 
the groundwork is laid, the true efficacy of PRP is yet 
to be determined. In addition to variation of blood cell 
components contained within each product, an indi-
vidual’s health, age and comorbidities may also reflect 
the effectiveness of PRP (26). 
MSCs
Mesenchymal stem cells (MSCs) are multipotent 
cells present in the stroma of many human organs and 
tissues. The best source of adult MSCs remains unclear. 
Several different tissues have been explored including 
bone marrow, adipose tissue, and umbilical cord tissue 
(Wharton’s jelly). Traditionally bone marrow has been 
used as a source of MSCs, though research has shown a 
relative paucity of MSCs within bone marrow aspirates 
(BMA) comprising only .001-.02% of mononucleated 
cells isolated from aspirates (27, 28). In comparison, 
human adipose tissue through a lipoaspirate proce-
dure, yields MSC numbers of ~1-7% of the nucleated 
cell population (29). Its ease of harvest and the rela-
tive abundance of MSCs in adipose tissue has seen this 
method increasingly used for autologous therapies. 
Indeed, Adipose-derived MSCs (ASCs) can be 
easily obtained by a minimal invasive surgical proce-
dure and expanded in vitro. In addition, ASCs have 
been shown to possess strong regenerative properties 
when transplanted in vivo in experimental animal 
models (30, 31). and this potential may be used to re-
generate damaged tissues. In addition, MSCs secrete 
a variety of bioactive molecules that act in a paracrine 
way to prime and sustain angiogenic, antifibrotic, an-
tiapoptotic, and immunomodulatory responses in tar-
get tissue (32). Adipose-derived MSCs routinely are 
obtained enzymatically from fat lipoaspirates (LP) 
and may undergo prolonged ex vivo expansion, with 
significant senescence and a decline in multipotency. 
In addition, the technique is fraught with complex 
regulatory issues.  For these reasons, Tremolada and 
colleagues (33) recently developed an enzyme free 
technology able to obtain a micro-fragmented fat 
preparation containing a significant number of Ad-
MSCs. Adipose tissue is the ideal source for extracting 
MSCs because it can be easily accessed and harvested 
via a minimally invasive surgical procedure, it may be 
found in large quantities in most people, and it guar-
antees an adequate amount of stem cells with good vi-
ability and age-related differentiating potential.
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Discussion
Actual surgical treatments for osteochondral le-
sions and early knee osteoarthritis seem to be promis-
ing. Microfractures, are often considered the first-line 
surgical treatment option due to the low costs and ease 
of the technique (34-38), while ACI is rather reserved 
as a salvage procedure (39-41, 45).
On the other hand, MF are supposed to have 
long-term limits in clinical outcome, related to the 
poor biomechanical characters of fibrous cartilage, 
though evidence provided by literature reports no sig-
nificant differences (20-24).
OAT, ACI and MACI techniques are widely used 
in the clinical practice and showed good results in the 
mid and long-term follow-up. However, the costs and 
the unavailability of allograft tissue in all centers make 
these techniques more difficult to perform if compared 
to the microfractures.
Biological derivates, such as platelet-rich plasma 
and mesenchymal stem cells, have been introduced in 
clinical practice to improve the quality of regenerative 
tissue (42). 
Many studies on PRP have been conducted, how-
ever, the true efficacy of this technique alone is yet to 
be determined. Growth factors could have contradict-
ing roles, depending on the in vivo model used. For 
example, in the work of 2013 Ellman et al, found out 
FGF-2 accelerates spontaneous and induced OA de-
velopment in humans, whereas in murine model it has 
a chondroprotective action (43). In addition to the 
variation of blood cell components contained within 
each product, individual’s health, age and comorbidi-
ties may also reflect the effectiveness of PRP, so actual 
results are still inconsistent.
Natural and physical therapies have been used in 
orthopaedics and traumatology (44, 45). Gang-Hua 
Cui and coll. recently published a meta-analysis on the 
efficacy of MSCs treatment in KOA (46). They con-
cur that MSC treatment seem to significantly improve 
pain and function and the effectiveness do not reduce 
over time. The optimal dose and vehicle are yet to be 
established. However, in the last years there has been a 
greater interest in the adipose-derived MSC treatment 
due to its ease of harvest and availability of adipose 
tissue. This technique seem to collect higher MSCs 
concentrations and to yield superior results. Further 
control studies will be necessary to confirm these pre-
liminary results of treatments with MSCs and their 
biological action.
Conclusions
In conclusion, treatment of early knee osteoarthri-
tis and chondral lesions is still a challenging problem. 
Current surgical treatments, such as microfractures, 
ACI and OAT, are the best options available, though 
it could be hard to increase the use of ACI and OAT 
because of similar results and higher costs, if compared 
with MF. Biological augmentations could be the solu-
tion to enhancing the outcomes of a simple technique. 
PRP seems to be promising but true efficacy is yet to 
be determined. The attention is recently focused on the 
more encouraging results on MSCs and ASCs. Never-
theless large cohort studies with long term follow-up 
are needed to understand the biological action and the 
real benefits of this techniques.”
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